CD8A and neoplasm: The adaptive T-cell response is the major target of PD-1/PD-L1 axis blockade and, understandably, most studies aiming to decipher resistance mechanisms and to identify biomarkers of response were focused on CD8 T cells, which directly recognize and kill tumor cells [24].